Perrigo's generics split is back on the docket, thanks to $1.55B Altaris offer
Perrigo is selling its prescription generics business to Altaris Capital Partners for $1.55 billion. The generics unit, which recently nabbed approval for a copycat version of Teva's ProAir HFA inhaler, will establish itself as a standalone company, investment firm Altaris said. The deal is expected to close by the end of the third quarter.
Source: fiercepharma.com